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Abstract
Background: Myostatin (MSTN) is a transforming growth factor-ß superfamily member that acts as a major regulator
of skeletal muscle mass. GDF-11, which is highly related to MSTN, plays multiple roles during embryonic develop‑
ment, including regulating development of the axial skeleton, kidneys, nervous system, and pancreas. As MSTN and
GDF-11 share a high degree of amino acid sequence identity, behave virtually identically in cell culture assays, and uti‑
lize similar regulatory and signaling components, a critical question is whether their distinct biological functions result
from inherent differences in their abilities to interact with specific regulatory and signaling components or whether
their distinct biological functions mainly reflect their differing temporal and spatial patterns of expression.
Methods: We generated and characterized mice in which we precisely replaced in the germline the portion of the
Mstn gene encoding the mature C-terminal peptide with the corresponding region of Gdf11.
Results: In mice homozygous for the knock-in allele, all of the circulating MSTN protein was replaced with GDF-11,
resulting in ~ 30–40-fold increased levels of circulating GDF-11. Male mice homozygous for the knock-in allele had
slightly decreased muscle weights, slightly increased weight gain in response to a high-fat diet, slightly increased
plasma cholesterol and HDL levels, and significantly decreased bone density and bone mass, whereas female mice
were mostly unaffected.
Conclusions: GDF-11 appears to be capable of nearly completely functionally replacing MSTN in the control of mus‑
cle mass. The developmental and physiological consequences of replacing MSTN with GDF-11 are strikingly limited.
Keywords: Myostatin, GDF-11, Gene knock-in, Body composition, Muscle, Fat, Bone, Metabolism
Background
Myostatin (MSTN) is a transforming growth factor-ß
(TGF-ß) superfamily member that normally acts to limit
skeletal muscle mass [1]. Mice lacking MSTN exhibit
dramatic increases in muscle mass throughout the body,
with individual muscles growing to about twice the normal size. MSTN has been highly conserved through
evolution [2], and naturally occurring and engineered
mutations in the MSTN gene also have been shown
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to result in increased muscle mass and/or function in
numerous other mammalian [2–16], piscine [17–19], and
avian [20, 21] species. Loss of MSTN leads to both an
increase in the number of muscle fibers that are formed
during development and an increase in the sizes of individual fibers [1]. Postnatally, MSTN is made by myofibers [1], circulates in the blood [22], and signals back to
myofibers to limit growth [23, 24]. Based on this postnatal function of MSTN, numerous pharmaceutical and
biotechnology companies have developed MSTN inhibitors that have been tested in clinical trials in patients with
muscle and metabolic diseases (for review, see ref. [25]).
GDF-11, which was originally identified using Mstn
as a probe [1], is a highly related TGF-ß family member
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that is about 90% identical to MSTN in the mature portion of the protein [26, 27]. Gene targeting studies in
mice showed that the function of GDF-11 is distinct from
that of MSTN. During embryogenesis, GDF-11 has been
shown to regulate anterior-posterior patterning of the
axial skeleton [28] as well as the development of the kidney [29], pancreas [30, 31], and nervous system [32–34].
Although the phenotypes of Mstn−/− and Gdf11−/− mice
appear to be mostly non-overlapping, the two genes have
been shown to be at least partially functionally redundant
with respect to anterior-posterior axial patterning [35].
Much less is known about adult functions of GDF-11, as
Gdf11−/− mice die within the first 24 h after birth.
MSTN and GDF-11 are nearly indistinguishable in cell
culture assays and also share many regulatory and signaling mechanisms and components. MSTN is synthesized
in precursor form, and following proteolytic processing, the C-terminal dimer, which is the actual signaling
molecule, remains non-covalently bound to the propeptide in an inactive, latent state [36, 37]. The MSTN latent
complex can be activated by proteolytic cleavage of the
propeptide by members of the BMP-1/tolloid family of
metalloproteases [38], which appears to be the dominant mechanism operating in vivo [39]. Similarly, the
C-terminal dimer and propeptide of GDF-11 also form
a latent complex that can be activated by BMP-1/tolloid proteases [40]. MSTN is regulated extracellularly
by other binding proteins as well, including follistatin (FST) [36], FSTL-3 [41], GASP-1, and GASP-2 [42].
Genetic studies have shown that loss of FST [43–45] and/
or GASP-1/GASP-2 [46] results in decreases in muscle mass and fiber type shifts consistent with their roles
in inhibiting MSTN in vivo. These binding proteins are
also capable of inhibiting GDF-11, and mice lacking FST
[43] or GASP-1/GASP-2 [46] also exhibit axial patterning defects consistent with increased activity of GDF-11.
Finally, when free of inhibitory binding proteins, MSTN
is capable of binding the type 2 receptors, ACVR2 and
ACVR2B [36], and the type 1 receptors, ALK4 and ALK5
[47]. Targeting these receptors in mice leads to increased
muscle mass, consistent with the key roles that these
receptors play in mediating MSTN signaling in vivo [24,
48]. GDF-11 is capable of binding to these same receptors, and Acvr2 and Acvr2b mutant mice exhibit axial
patterning and kidney defects [49–53] similar to those
seen in Gdf11 mutants.
Given that MSTN and GDF-11 share a high degree of
amino acid sequence identity, behave virtually identically in cell culture assays, and utilize similar regulatory
and signaling components, a critical question is whether
their distinct biological functions result from inherent differences in their abilities to interact with specific
regulatory and signaling components or whether their
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distinct biological functions mainly reflect their differing
temporal and spatial patterns of expression. Given that
both MSTN and GDF-11 circulate in the blood, another
critical question is whether these ligands act locally or
systemically in signaling to target cells. Genetic studies
have suggested that MSTN has both autocrine/paracrine
and endocrine modes of action [54], although very little
is known about the functions of GDF-11 and its mode
of action in adult animals. Although overexpression of
either MSTN [22] or GDF-11 [55, 56] has been shown to
induce a cachexia-like syndrome in adult mice, at least
one study has reported distinct effects of giving MSTN
and GDF-11 protein exogenously to mice, suggesting
that these two molecules may have inherent differences
in their biological properties [57]. Here, we addressed the
functional equivalence of these two molecules by replacing the portion of the Mstn gene encoding its mature
domain with the corresponding portion of Gdf11 in the
germline of mice.

Methods
All animal experiments were carried out in accordance
with protocols that were approved by the Institutional
Animal Care and Use Committees at the University of
Connecticut School of Medicine and Johns Hopkins University School of Medicine. To generate mice carrying a
MstnGdf11 knock-in allele, the targeting construct was
electroporated into embryonic stem (ES) cells, and ES
cell colonies carrying the homologously targeted allele
were injected into blastocysts. Chimeric mice generated from these blastocysts were bred to identify those
exhibiting germline transmission of the targeted allele.
Offspring from these matings were then bred with EIIaCre transgenic mice [58] in order to delete the neomycin
resistance cassette in the germline. From these crosses,
we obtained mice carrying the MstnGdf11 knock-in allele
lacking the neo-cassette.
Circulating MSTN and GDF-11 levels were determined using a liquid chromatography-tandem mass
spectrometry assay, as described [59]. There was no
detectable cross-reactivity of MSTN in the GDF-11
assay or of GDF-11 in the MSTN assay; the addition of
up to 100 ng/mL of GDF-11 did not significantly affect
GDF-8 measurement, and addition of up to 100 ng/mL
GDF-8 did not affect GDF-11 measurement. The lower
limit of quantitation was 0.5 ng/mL for GDF-8 as well as
for GDF-11. The linear range of the assay was from 0 to
100 ng/mL for both. The inter-assay coefficients of variation in the MSTN assay were 15.1%, 11.3%, and 7.4% in
the low- (8.7 ng/mL), medium- (51.1 ng/mL), and high(97.6 ng/mL) quality control pools, respectively, and
the corresponding CVs in the GDF-11 assay were 8.7%,
12.8%, and 17.1% in the low- (3.4 ng/mL), medium- (52.0
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ng/ml), and high- (104.7 ng/ml) quality control pools,
respectively [59].
For measurement of muscle weights, individual muscles were dissected from both sides of 10-week-old mice,
and the average weight was used for each muscle. Serial
sections (15 μm) were cut transversely through the widest point of the gastrocnemius muscle using a cryostat.
Fiber type analysis was carried out using antibodies (BAD5, SC-71, and BF-F3 for myosin heavy chains type I, IIa,
and IIb, respectively) developed by Schiaffino et al. [60]
and obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the National
Institute of Child Health and Human Development
and maintained by the University of Iowa. Live animal
imaging was performed using a Piximus dual-energy
X-ray absorptiometer (DXA). Glucose tolerance tests
(GTT) were performed by administering an intraperitoneal injection of 1 g glucose/kg body weight following a
6-h fast. Mice were then placed on a 60-kcal % fat diet
(D12492, Research Diets, Inc.), and a repeat GTT was
performed after 4 weeks; mice were then maintained on
the high-fat diet for an additional 4 weeks. For analysis
of skeletal patterning, newborn mice were euthanized,
skinned, eviscerated, fixed in 80% ethanol, and dehydrated in 95% ethanol for 1 day and acetone for 3 days.
Skeletons were stained in 10% acetic acid in ethanol containing 0.003% Alizarin red and 0.0045% Alcian blue for
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36 h. After staining, skeletons were cleared in 1% potassium hydroxide and transferred to 20%, 50%, 80%, and
100% glycerol over several days. For microCT analysis,
the left femur, left humerus, and lumbar vertebrae were
placed in 70% ethanol. μCT was performed in a Scanco
μCT40 at 8 μm3 resolution. Samples were scanned in 70%
ethanol 55 kVp, 145 μA intensity, and 300 ms. The instrument is calibrated weekly using Scanco phantoms, and all
scans passed routine quality control verification. Analysis
of bones was conducted using standard protocols, with a
lower threshold of 2485 HU for femoral trabeculae, 4932
HU for femoral cortex, and 3078 HU for vertebral trabeculae [61]. Surface renderings were generated corresponding to each of these thresholds. For all data, statistical
significance was assessed using Student’s t test.

Results, discussion, and conclusions
As one approach to determine whether there are fundamental inherent differences between MSTN and
GDF-11 that can lead to distinct biological activities
in vivo, we analyzed the effect of replacing MSTN with
GDF-11 in the germline. As shown in Fig. 1, the Mstn
gene contains three exons, with the mature C-terminal
domain being encoded within exon 3. We generated a
targeting construct in which we precisely replaced the
coding sequence for the MSTN C-terminal domain,
starting at the furin proteolytic processing site, with

Fig. 1 Schematic of the Mstn locus with the locations of the coding segments shown as blue boxes and the sequence of the coding portion of
exon 3 shown below. The segment encoding the mature C-terminal domain following the furin processing site is shown in red. In the targeting
construct, this segment was replaced precisely with the corresponding segment taken from Gdf11. The neo-cassette, introduced into intron 2 for
selection of ES cells, was removed using a germline-expressed cre recombinase, leaving behind a single LoxP site in intron 2. All studies were carried
out after crossing the neo-deleted allele (MstnGdf11) onto a C57BL/6 genetic background. X, XbaI; H, HindIII; E, EcoRI
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that encoding the GDF-11 C-terminal domain. Hence,
this knock-in allele (MstnGdf11) encodes a hybrid precursor protein consisting of the MSTN propeptide and
the GDF-11 C-terminal domain, and following proteolytic processing, the mature GDF-11 signaling molecule
would be produced wherever MSTN would normally
be produced. A previous study showed that the MSTN
propeptide is capable of binding and inhibiting the
GDF-11 C-terminal dimer [37], so our expectation
was that the MSTN propeptide from this hybrid protein would be capable of maintaining the mature GDF11 C-terminal dimer in a latent state, as is the case for
mature MSTN [36]. Following homologous recombination in embryonic stem cells, injection of the targeted
cells into blastocysts, and transfer of the blastocysts to
pseudopregnant females, we obtained chimeric mice
that transferred the knock-in allele (MstnGdf11) through
the germline. After removing the neo-cassette using a
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germline expressed cre transgene [58], we backcrossed
the knock-in allele 5 generations onto a C57BL/6
genetic background prior to analysis.
MstnGdf11/Gdf11 mice were viable, and we carried out
all analysis on 10-week-old Mstn+/+, Mstn+/Gdf11, and
MstnGdf11/Gdf11 mice that we generated from inter-crosses
of Mstn+/Gdf11 mice. We first measured MSTN and GDF11 protein levels in the plasma of these mice using a liquid chromatography-tandem mass spectrometry assay
highly specific for each protein [59]. As shown in Fig. 2,
wild-type mice had circulating MSTN and GDF-11 levels
in the range of ~ 150 ng/ml and ~ 4 ng/ml, respectively.
Mice carrying the MstnGdf11 allele showed circulating
levels of MSTN and GDF-11 consistent with a complete replacement of MSTN with GDF-11. In particular,
MstnGdf11/Gdf11 mice had no detectable circulating MSTN
and had levels of circulating GDF-11 comparable to the
normal levels of MSTN, which is ~ 30–40-fold higher

Fig. 2 MSTN and GDF-11 plasma levels. Numbers of male (M) and female (F) mice were n = 6M, 6F for Mstn+/+, n = 6M, 6F for Mstn−/−, n = 6M, 4F
for Mstn+/Gdf11, and n = 5M, 5F for MstnGdf11/Gdf11. p < 0.001 for all comparisons of MSTN or GDF-11 levels between groups, except for MSTN values
between Mstn−/− and MstnGdf11/Gdf11 mice and GDF-11 values between Mstn+/+ and Mstn−/− mice, which were not significant

Lee et al. Skeletal Muscle

(2022) 12:7

Page 5 of 12

than the normal circulating levels of GDF-11. Mstn+/Gdf11
mice had intermediate levels of both proteins.
To determine whether GDF-11 can functionally
replace MSTN, we first examined body composition.
In 10-week-old mice, total body weights and lean body
mass (by DXA analysis) showed a small (~ 6–8%) but
statistically significant decrease in MstnGdf11/Gdf11

compared to Mstn+/+ mice in males but not in females
(Table 1). Consistent with these decreases in lean
body mass, the MstnGdf11 allele had a dose-dependent
effect on muscle mass in males, with individual muscles of MstnGdf11/Gdf11 mice weighing approximately
10% less than those of Mstn+/+ mice and Mstn+/
Gdf11
mice exhibiting an intermediate effect (Table 2);

Table 1 DXA and fasting blood/plasma analysis

Body weight (g)
DXA
Lean mass (g)
Fat mass (g)
BMD (g/cm2)
   Whole body
  Right humerus
  Left humerus
  Right femur
  Left femur
  L2 + L3 vertebrae
  L4 + L5 vertebrae

Glucose (mg/dL)
Standard diet
High-fat diet
Insulin (ng/ml)
Standard diet
High-fat diet
Leptin (ng/ml)
Standard diet
High-fat diet

Cholesterol (mg/dL)
Standard diet
High-fat diet
HDL (mg/dL)
Standard diet
High-fat diet
LDL (mg/dL)
Standard diet
High-fat diet
Trigylcerides (mg/dL)
Standard diet
High-fat diet
Free fatty acids (mEq/L)
Standard diet
High fat diet

Male
+/+

Male
Gdf11/Gdf11

Female
+/+

Female
Gdf11/Gdf11

25.2 ± 0.5 (23)

23.7 ± 0.3b (30)

20.0 ± 0.3 (19)

19.5 ± 0.3 (26)

19.6 ± 0.6 (12)

18.0 ± 0.4a (11)

0.0465 ± 0.0008 (12)

0.0443 ± 0.0005a (11)

2.9 ± 0.2 (12)

0.0405 ± 0.0008 (12)

b
c

p < 0.05 vs. +/+

p < 0.01 vs. +/+

p < 0.001 vs. +/+

0.0629 ± 0.0011a (11)

0.0615 ± 0.0008 (8)

0.0608 ± 0.0006 (12)

0.0678 ± 0.0016a (11)

0.0580 ± 0.0010 (12)
160.9 ± 5.8 (18)

207.6 ± 8.1 (10)

0.97 ± 0.17 (10)

3.33 ± 0.50 (10)
2.76 ± 0.66 (10)

0.0504 ± 0.0012a (11)

139.6 ± 4.1a (17)

209.1 ± 6.1 (9)

0.93 ± 0.09 (14)

4.38 ± 0.63 (14)
4.04 ± 0.50 (14)

116.6 ± 1.4c (14)

76.6 ± 3.5 (10)

0.69 ± 0.06 (10)

0.63 ± 0.02 (10)

0.0534 ± 0.0011 (12)

127.8 ± 4.2 (13)

98.9 ± 2.2 (10)

93.9 ± 3.0 (10)

0.0627 ± 0.0006 (12)

161.2 ± 3.3 (22)

168.6 ± 3.3c (14)

1.94 ± 0.46 (10)

0.0534 ± 0.0012 (8)

0.0588 ± 0.0013 (12)

141.1 ± 3.5 (10)

2.90 ± 0.67 (10)

0.0635 ± 0.0013 (8)

0.0419 ± 0.0007 (12)

0.0602 ± 0.0023 (8)

58.26 ± 9.47 (14)

131.7 ± 6.2 (10)

0.0414 ± 0.0009 (8)

0.0547 ± 0.0015 (11)

52.82 ± 7.76 (10)

192.1 ± 11.5 (10)

0.0440 ± 0.0004 (12)

0.0390 ± 0.0006 (12)

0.0756 ± 0.0026 (12)

0.0537 ± 0.0011 (12)

0.0447 ± 0.0003 (8)

15.0 ± 0.3 (12)

2.3 ± 0.1 (12)

0.0395 ± 0.0006 (8)

0.0409 ± 0.0007b (11)

0.0693 ± 0.0025 (12)

15.7 ± 0.3 (8)

2.3 ± 0.1 (8)

0.0388 ± 0.0004 (11)

0.0444 ± 0.0011 (12)

Numbers of mice analyzed are shown in parentheses
a

3.0 ± 0.1 (11)

237.4 ± 13.9a (14)

151.5 ± 5.5a (14)

2.03 ± 0.20 (14)

5.16 ± 0.82 (14)
69.2 ± 1.8 (14)

87.6 ± 1.9 (14)

0.61 ± 0.03 (14)

0.57 ± 0.02 (14)

148.3 ± 11.0 (7)

0.46 ± 0.18 (7)

0.61 ± 0.17 (7)
2.30 ± 0.49 (7)

20.93 ± 8.55 (7)
117.7 ± 7.5 (7)

139.3 ± 10.3 (7)
79.0 ± 4.5 (7)

100.1 ± 6.4 (7)
6.83 ± 0.74 (7)

5.32 ± 0.34 (7)
69.4 ± 3.7 (7)

71.4 ± 5.3 (7)

0.61 ± 0.06 (7)

0.56 ± 0.05 (7)

161.3 ± 10.9 (7)

0.25 ± 0.07 (10)

0.98 ± 0.35 (10)
2.60 ± 0.32 (10)

26.91 ± 8.58 (10)
118.6 ± 5.3 (10)

154.4 ± 9.6 (10)
78.8 ± 3.1 (10)

109.1 ± 6.1 (10)
7.08 ± 0.46 (10)

6.46 ± 0.62 (10)
60.9 ± 3.8 (10)

71.3 ± 6.4 (10)

0.71 ± 0.17 (10)

0.55 ± 0.07 (10)
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Table 2 Muscle weights (mg)
Pectoralis

Triceps

Quadriceps

Gastrocnemius

78.3 ± 2.1

108.3 ± 3.5

198.5 ± 5.9

138.4 ± 3.0

Males
+/+ (n = 11)

+/Gdf11 (n = 28)

Gdf11/Gdf11 (n = 19)

Females

+/+ (n = 11)

+/Gdf11 (n = 19)

a
b
c

Gdf11/Gdf11 (n = 14)

70.5 ± 1.1b
c

65.4 ± 1.7

52.9 ± 1.1

51.8 ± 1.1

49.5 ± 1.5

99.8 ± 1.7a
a

97.6 ± 2.1
77.9 ± 1.0

77.7 ± 1.5

75.1 ± 1.2

185.5 ± 3.0

b

173.7 ± 3.3

148.8 ± 2.2

146.8 ± 2.1

141.6 ± 3.5

130.9 ± 1.8a

121.5 ± 1.7c
102.5 ± 1.4

102.9 ± 1.8

98.3 ± 2.3

p < 0.05 vs. +/+

p < 0.01 vs. +/+

p < 0.001 vs. +/+

Fig. 3 A Representative sections of gastrocnemius muscles stained with H&E (upper panels) or analyzed by immunofluorescence for different fiber
types (middle and lower panels). Please note that the three images for a given genotype were not taken from adjacent sections. B Weight gain on
high-fat diets for Mstn+/+ (n = 6M, 6F, black lines) and MstnGdf11/Gdf11 (n = 5M, 5F, red lines) mice. *p < 0.05. C Glucose tolerance tests on Mstn+/+
(black lines) and MstnGdf11/Gdf11 (red lines) mice. Numbers of mice were n = 9M, 6F for Mstn+/+, and n = 9M, 7F for MstnGdf11/Gdf11 for mice on standard
diets, and n = 10M, 7F for Mstn+/+ and n = 9M, 7F for MstnGdf11/Gdf11 for mice on high-fat diets. None of the differences at any time point were
statistically significant

differences in muscle weights between MstnGdf11/Gdf11
and Mstn+/+ female mice were not statistically significant. The fact that muscle weights were not increased
in MstnGdf11/Gdf11 mice implies that GDF-11 can functionally substitute for MSTN in negatively regulating muscle mass. Moreover, the fact that weights are
slightly decreased suggests that GDF-11 produced
from this knock-in allele may even be slightly more
active than endogenous MSTN. We also carried out
fiber type analysis, as loss of Mstn has been shown
to lead to shifts toward more glycolytic 2B fibers
[62]. As shown in Fig. 3A and Table 3, we found no
differences in the distribution of fiber types between
MstnGdf11/Gdf11 and Mstn+/+ mice.

Table 3 Fiber type numbers in gastrocnemius muscles
+/+ (n = 3)
Total fibers
Type I fibers
Type IIa fibers
Type IIb fibers

8295 ± 357

130 ± 12

1446 ± 57

6398 ± 431

Gdf11/Gdf11 (n = 3)
8136 ± 103

126 ± 7

1540 ± 173

6473 ± 405

None of the differences between +/+ and Gdf11/Gdf11 mice are statistically
significant

In addition to regulating muscle mass, MSTN also
regulates body composition in terms of fat mass, with
Mstn−/− mice [63] as well as mice in which MSTN
receptors (ACVR2 and ACVR2B) have been targeted in
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myofibers [24] having reductions in total body fat. By
DXA analysis, we observed no differences in total body
fat content in MstnGdf11/Gdf11 compared to Mstn+/+ mice
(Table 1). In addition, we found no significant differences in plasma leptin levels in the knock-in mice compared to wild type mice. Mstn−/− mice have also been
shown to exhibit less weight gain when placed on highfat diets [64], which has also been seen in mice in which
Acvr2 and Acvr2b have been targeted in myofibers [24].
As shown in Fig. 3B, male MstnGdf11/Gdf11 mice actually
gained slightly more weight than Mstn+/+ mice when
placed on high-fat diets, although leptin levels were similar between MstnGdf11/Gdf11 and Mstn+/+ mice even after 8
weeks on the high-fat diet (Table 1); no significant differences in weight gains or leptin levels were seen in female
mice placed on high-fat diets. We also observed small,
but significant increases in plasma cholesterol and HDL
levels in male MstnGdf11/Gdf11 mice maintained on standard diets compared to Mstn+/+ mice (increased by 19%
and 18%, respectively) as well as following 8 weeks on a
high-fat diet (increased by 24% and 15%, respectively)
(Table 1). No differences were seen in LDL, triglyceride,
or free fatty acid levels in male MstnGdf11/Gdf11 mice or
in any of the lipid levels in female MstnGdf11/Gdf11 mice.
Hence, although some small differences in both skeletal
muscle mass and high-fat weight gain were seen in male
mutant mice, replacement of the MSTN mature domain
with that of GDF-11 had only a minor effect on overall
body composition.
The MSTN-GDF-11 regulatory system is also known
to have effects on glucose metabolism. In particular,
Mstn−/− mice are able to maintain normal or lower blood
glucose levels despite having lower insulin levels [24,
63]. In addition, GDF-11 is known to play an important
role in pancreatic development [30, 31], and administration of GDF-11, but not MSTN, protein to mice has been
shown to improve glucose tolerance [57]. As shown in
Table 1, fasting blood glucose levels were slightly higher
in MstnGdf11/Gdf11 females compared to Mstn+/+ controls
maintained on standard diets, but no statistically significant differences were seen in male mice on standard diets
or in either males or females maintained on high-fat diets
for 8 weeks. Moreover, MstnGdf11/Gdf11 and Mstn+/+ mice
exhibited similar responses to a glucose challenge in glucose tolerance tests, both in mice maintained on standard diets and in mice maintained on high-fat diets for 4
weeks (Fig. 3C). Hence, complete replacement of MSTN
with GDF-11 appeared to have very little effect on glucose metabolism.
In addition to analyzing whether GDF-11 can functionally replace MSTN, we also examined whether increased
expression of GDF-11 in these mice affects other biological processes known to be regulated by GDF-11. In

Page 7 of 12

particular, we examined whether axial skeleton patterning was affected in MstnGdf11/Gdf11 mice. Previous studies have shown that loss of GDF-11 leads to anteriorly
directed homeotic transformations of the axial skeleton
[28] and that loss of GDF-11 inhibitors, specifically FST
and/or GASP-1/GASP-2, leads to posteriorly directed
transformations [43, 46]. Analysis of Alizarin red- and
Alcian blue-stained skeletons prepared from 25 wild-type
and 30 MstnGdf11/Gdf11 newborn mice revealed the normal
pattern of 7 cervical, 13 thoracic, and 6 lumbar vertebrae
in all 55 mice. Moreover, in the cervical region, anterior
tuberculi were present on C6 in all mice, and in the thoracic region, the first seven ribs were attached to the sternum in all mice, with the last six ribs remaining floating.
Hence, axial skeletal patterning appeared to be normal
in MstnGdf11/Gdf11 newborn mice and did not exhibit the
posteriorly directed homeotic transformations that might
be predicted to result from excess GDF-11 activity.
Finally, we examined bones of MstnGdf11/Gdf11 mice.
Mstn−/− mice have been reported to have increased bone
density [65], possibly as a secondary effect of increased
muscling. The role of GDF-11 in regulating bone homeostasis has been controversial, with one study reporting a
decrease in bone density upon exogenous administration
of GDF-11 to adult mice [66] and another study reporting decreased bone mass not only in newborn Gdf11 null
mice but also in young adult mice in which tamoxifeninducible cre-mediated recombination was used to target a Gdf11flox allele [67]. Whatever specific role GDF-11
may play in bone, targeting the MSTN/GDF-11/activin A
signaling pathway, either pharmacologically using decoy
forms of ACVR2 [68] or ACVR2B [69–73] or genetically
by targeting Acvr2/Acvr2b [74] or Alk4/Alk5 [45] in osteoblasts, has been shown to cause significant increases in
bone mass and density. To assess possible effects of the
knock-in allele on bone, we first assessed bone density
by DXA. As shown in Table 1, we observed a small (~
5%) but significant decrease in whole body bone density
in MstnGdf11/Gdf11 male mice compared to Mstn+/+ control mice. Comparable differences were present in multiple regions of the body, including upper and lower limb
long bones as well as lumbar vertebrae, but no differences were seen in female mice. To analyze bone structure in greater detail, we carried out micro-CT analysis
of humeri, femurs, and lumbar vertebrae. As shown in
Table 4 and Fig. 4, numerous micro-CT parameters,
including bone surface, BV/TV, connectivity density, trabecular number, trabecular thickness, and bone mineral
density, were significantly decreased in MstnGdf11/Gdf11
compared to Mstn+/+ male mice; for example, BV/TV
and bone mineral density were reduced in femurs by 43%
and 48%, respectively, humeri by 26% and 34%, respectively, and L5 vertebrae by 19% and 22%, respectively.
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Table 4 MicroCT analysis (trabecular bone)
Male
+/+ (n = 9)

Male
Gdf11/Gdf11 (n = 8)

Female
+/+ (n = 7)

Female
Gdf11/Gdf11 (n = 10)

2.16 ± 0.08

1.86 ± 0.05b

1.75 ± 0.05

1.72 ± 0.04

13.03 ± 0.87b

9.36 ± 0.61

8.43 ± 0.78

Femurs
Total volume (mm3)
3

Bone volume ( mm )
Bone surface ( mm2)
Bone volume fraction (BV/TV) (%)
Bone surface density (1/mm)
Specific bone surface (1/mm)
Connectivity density (1/mm3)
Structure model index
Trabecular number (Tb.N) (1/mm)
Trabecular thickness (Tb.Th) (μm)
Trabecular spacing (Tb.Sp) (μm)
Standard deviation of Tb.Th (μm)
Standard deviation of Tb.Sp (μm)
Degree of anisotropy
Bone mineral density (mg/ccm HA)
Tissue density (mg/ccm HA)
Humeri
Total volume (mm3)
Bone volume (mm3)
Bone surface ( mm2)
Bone volume fraction (BV/TV) (%)
Bone surface density (1/mm)
Specific bone surface (1/mm)
Connectivity density (1/mm3)
Structure model index
Trabecular number (Tb.N) (1/mm)
Trabecular thickness (Tb.Th) (μm)
Trabecular spacing (Tb.Sp) (μm)
Standard deviation of Tb.Th (μm)
Standard deviation of Tb.Sp (μm)
Degree of anisotropy
Bone mineral density (mg/ccm HA)
Tissue density (mg/ccm HA)
L5 Vertebrae
Total volume (mm3)
Bone volume (mm3)
Bone surface ( mm2)
Bone volume fraction (BV/TV) (%)
Bone surface density (1/mm)
Specific bone surface (1/mm)
Connectivity density (1/mm3)
Structure model index
Trabecular number (Tb.N) (1/mm)
Trabecular thickness (Tb.Th) (μm)
Trabecular spacing (Tb.Sp) (μm)
Standard deviation of Tb.Th (μm)
Standard deviation of Tb.Sp (μm)
Degree of anisotropy
Bone mineral density (mg/ccm HA)
Tissue density (mg/ccm HA)
a

p < 0.05 vs. +/+
p < 0.01 vs. +/+
c
p < 0.001 vs. +/+
b

0.403 ± 0.058

21.49 ± 1.97

0.194 ± 0.015b

18.20 ± 2.04

10.34 ± 0.65b

57.70 ± 3.80

70.85 ± 2.58b

9.82 ± 0.56

246.4 ± 12.1

1.81 ± 0.19

6.95 ± 0.33c

179.1 ± 16.3b

2.52 ± 0.07b

5.61 ± 0.14

4.75 ± 0.14c

166.5 ± 5.6

204.6 ± 7.0c

48.0 ± 2.6

17.4 ± 1.5

40.5 ± 1.8a

5.84 ± 0.44

3.47 ± 0.23

2.91 ± 0.29

4.90 ± 0.38a
80.3 ± 14.4

13.5 ± 0.6

15.3 ± 1.0

16.1 ± 0.7

1.80 ± 0.05

1.80 ± 0.04

1.81 ± 0.04

901.5 ± 5.8

908.1 ± 7.8

928.5 ± 9.4

1.98 ± 0.05

2.03 ± 0.07

2.04 ± 0.05

22.91 ± 1.04a

22.49 ± 0.72

21.41 ± 0.70

0.417 ± 0.020b

55.45 ± 0.29b

11.55 ± 0.28b
266.9 ± 13.3a

0.87 ± 0.05c

5.59 ± 0.08

5.21 ± 0.08b

166.2 ± 2.8

180.1 ± 3.5b

73.8 ± 2.2

2.01 ± 0.04

231.0 ± 8.7

906.7 ± 6.2

69.73 ± 1.41

47.0 ± 8.6

41.4 ± 0.9

49.90 ± 1.43

13.8 ± 1.0

49.4 ± 5.4

3.73 ± 0.32

40.6 ± 1.4

20.98 ± 0.56c

46.3 ± 1.6

69.76 ± 2.27

5.75 ± 0.52

38.0 ± 1.0

26.05 ± 0.92

0.46 ± 0.08

4.21 ± 0.20

3.06 ± 0.12

50.0 ± 6.1b

306.1 ± 10.5

6.52 ± 0.46

0.045 ± 0.005

2.89 ± 0.08

75.5 ± 5.8

12.90 ± 0.21

0.054 ± 0.005

3.03 ± 0.07

68.5 ± 3.0b

26.63 ± 1.03

47.0 ± 5.2

4.44 ± 0.51a

57.6 ± 1.8

2.06 ± 0.06

54.8 ± 4.9

75.1 ± 2.9

0.77 ± 0.02

220.9 ± 6.7a

0.541 ± 0.034

69.3 ± 2.8

0.82 ± 0.03

195.2 ± 6.8

910.4 ± 7.8

248.3 ± 8.2

0.90 ± 0.03

0.063 ± 0.008a

4.46 ± 0.13a

1.83 ± 0.02

39.5 ± 0.8

857.6 ± 4.9

4.99 ± 0.15

14.5 ± 0.8

235.4 ± 4.6

4.01 ± 0.13

856.9 ± 4.6

76.32 ± 1.84a

40.4 ± 1.2

40.2 ± 0.6

2.81 ± 0.07

854.5 ± 10.0

70.86 ± 1.97
2.86 ± 0.06

4.18 ± 0.08

97.0 ± 13.1

1.56 ± 0.04

6.97 ± 0.62b

117.5 ± 12.9

2.75 ± 0.08

73.79 ± 1.92

1.61 ± 0.03

9.36 ± 0.59
6.21 ± 0.37

104.4 ± 10.5

4.86 ± 0.36

1.53 ± 0.03a
79.7 ± 6.1b

0.93 ± 0.02

71.55 ± 1.77

7.01 ± 0.57

15.0 ± 0.68

153.5 ± 18.7

0.088 ± 0.007

5.35 ± 0.28

15.0 ± 0.14

66.0 ± 2.2b

876.7 ± 7.5

7.92 ± 0.55

0.121 ± 0.012

14.2 ± 1.1

53.8 ± 2.5

1.67 ± 0.05

0.139 ± 0.011

41.6 ± 0.2a
11.4 ± 0.1a
75.2 ± 4.4

3.71 ± 0.06
268.7 ± 5.1
94.0 ± 8.0
43.0 ± 3.4

0.427 ± 0.019
21.03 ± 0.38
11.11 ± 0.10
53.31 ± 1.03
280.9 ± 12.0
0.81 ± 0.04
4.81 ± 0.06
43.7 ± 0.7

198.6 ± 3.2
12.6 ± 0.19

85.2 ± 3.5

3.63 ± 0.12
277.6 ± 9.5
87.4 ± 5.0
37.1 ± 4.7

0.397 ± 0.015
19.40 ± 0.49a
10.48 ± 0.22a
54.57 ± 0.65
253.9 ± 7.8
0.91 ± 0.05
4.63 ± 0.07
43.1 ± 0.5

207.4 ± 3.8
12.7 ± 0.27

91.4 ± 2.8

1.98 ± 0.04

1.96 ± 0.04

1.96 ± 0.02

887.9 ± 1.7a

873.4 ± 6.6

879.1 ± 3.5

181.3 ± 5.6c

180.6 ± 4.1

164.9 ± 4.9a
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Mstn +/+

Mstn Gdf11/Gdf11

FEMURS

HUMERI

L5 VERTEBRAE

Fig. 4 Micro-CT images of representative femurs, humeri, and L5 vertebrae isolated from male Mstn+/+ and MstnGdf11/Gdf11 mice

Consistent with the DXA data, the only significant differences seen in micro-CT parameters in females were small
decreases in BV/TV and bone mineral density (reduced
by 8% and 9%, respectively) in L5 vertebrae.
Two general conclusions seem evident from the results
presented here. First, mature GDF-11 appears to be capable of completely functionally replacing mature MSTN
with respect to the control of muscle mass; in fact, based
on the slight decreases in muscle mass seen in MstnGdf11/
Gdf11
male mice, mature GDF-11 made from the knock-in
allele actually seems to be even more active than mature
MSTN in the control of muscle mass. We did observe
trends toward higher levels of circulating GDF-11 resulting from expression of the knock-in allele compared
to circulating MSTN levels resulting from expression
from the wild-type allele in male mice, but these differences were not statistically significant. This enhanced
activity in mice carrying the knock-in allele could reflect
either inherent differences in the biological properties
of mature MSTN versus mature GDF-11 or differences
in levels of activation of the latent MSTN complex versus the hybrid latent complex of mature GDF-11 bound
to the MSTN propeptide. Second, complete replacement
of mature MSTN with mature GDF-11 does not lead to
some of the developmental or physiological changes
that might be expected as a result of overexpression of
GDF-11. Developmentally, MstnGdf11/Gdf11 mice appear
to exhibit completely normal axial skeletal patterning.

This might not be surprising given that Gdf11 and Mstn
have distinct expression patterns during embryogenesis,
with Gdf11 being expressed in the tail bud and primitive
streak region in mid-gestation embryos [28] and Mstn
being expressed in the myotome compartment of developing somites [1]. Despite these distinct expression patterns, however, the two genes are known to be partially
functionally redundant with respect to axial patterning, with Gdf11/Mstn double mutants exhibiting more
extensive anteriorly directed homeotic transformations
than Gdf11 single mutants [35]. Hence, the normal skeletal patterning seen in MstnGdf11/Gdf11 mice suggests that
the biological activities of mature GDF-11 and mature
MSTN are similar with respect to regulation of axial
patterning. Physiologically, MstnGdf11/Gdf11 mice appear
to be relatively normal with respect to glucose metabolism despite having circulating GDF-11 levels that are
increased ~ 30–40-fold. Based on the report that purified GDF-11 but not MSTN can improve glucose tolerance [57], one might have expected MstnGdf11/Gdf11 mice
to have improved responses to glucose challenges compared to wild-type mice, but we observed no significant
differences between MstnGdf11/Gdf11 and wild-type mice
in glucose tolerance tests on either standard or high-fat
diets. We did observe trends toward lower glucose values
in glucose tolerance tests in mice maintained on high-fat
diets, but these differences were not statistically significant, and in fact, MstnGdf11/Gdf11 female mice actually had
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slightly elevated fasting glucose levels that were statistically significant.
One tissue that was substantially affected by replacing
MSTN with GDF-11 was bone, with MstnGdf11/Gdf11 mice
exhibiting significantly decreased BV/TV, trabecular
number, trabecular thickness, and bone mineral density,
at least in males. Although there are conflicting reports as
to the role of GDF-11 in regulating bone, the phenotype
of MstnGdf11/Gdf11 mice is consistent with the effects that
have been observed upon blocking this pathway pharmacologically using decoy forms of activin type 2 receptors [68–73] or genetically targeting Acvr2/Acvr2b [74] or
Alk4/Alk5 [45] in osteoblasts. The decreased bone mass
seen in MstnGdf11/Gdf11 mice would be consistent with the
possibility that GDF-11 made from the hybrid precursor
protein is slightly more active than endogenous MSTN,
as suggested by the slight decreases in muscle mass seen
in the knock-in mice. Alternatively, the bone phenotype
could result from increased GDF-11 levels per se, perhaps reflecting inherent differences between GDF-11 and
MSTN in their ability to regulate bone.
In interpreting the results of these studies, it is important to keep in mind not only that GDF-11 is expressed
under the control of Mstn regulatory sequences in these
knock-in mice but also that GDF-11 protein is made from
a hybrid precursor protein containing the MSTN propeptide. Although the MSTN propeptide and GDF-11
propeptide are each capable of binding mature GDF-11
and being cleaved by BMP-1/tolloid proteases to activate latency [37, 38, 40], it is possible that these propeptides have distinct properties that confer some degree of
specificity with respect to the biological functions carried
out by MSTN versus GDF-11. Hence, additional experiments, such as germline replacement of the MSTN propeptide with the GDF-11 propeptide or the converse
germline replacement of the GDF-11 propeptide and/
or mature domain with the corresponding portions of
MSTN, will be required to understand the full extent to
which the various domains of these molecules are functionally equivalent.
Our findings are significant in the context of the current uncertainty surrounding the biological activity of
GDF-11 in vivo. A series of papers have suggested that
GDF-11 may play a key role in tissue aging. Circulating
GDF-11 levels in mice have been reported to decline during aging [75], and injection of purified GDF-11 protein
to aged mice was shown to reverse age-related cardiac
hypertrophy [75], stimulate vascular remodeling and
enhance neurogenesis in the nervous system of aged
mice [76], and improve satellite cell function and muscle
regeneration and function in aged mice [77]. These studies have suggested that restoring GDF-11 levels to youthful levels may be a new therapeutic strategy to prevent
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or reverse age-related tissue dysfunction in a wide range
of tissues. Some other studies have not found a decline
in GDF-11 levels during aging. Subsequent studies
have suggested that the assay used to measure circulating levels of GDF-11 may have been detecting circulating MSTN and that GDF-11 levels are either unchanged
or perhaps even increased during aging [59, 78, 79]. The
reported effect of GDF-11 in promoting muscle regeneration also has remained uncertain; this finding was
unexpected given that loss or inhibition of MSTN signaling had been shown to improve muscle regeneration in
the setting of both acute muscle injury and chronic muscle degeneration (for reviews, see references [80–82]).
Indeed, subsequent studies reported that administering
purified GDF-11 to mice impairs the ability of the muscle
to regenerate [78, 83], which is more consistent with the
fact that MSTN and GDF-11 are virtually indistinguishable in their biological properties in vitro. Although it is
possible that differences in the experimental procedures
and dose regimens used may account for the discrepant
findings among studies and that exogenously administered GDF-11 may behave differently than endogenously
produced MSTN, our findings are consistent with GDF11 being capable of functionally replacing MSTN in vivo.
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